



Synthesis and SAR Studies of Some Novel Series of Pyrimidine Analogues

BALAKRISHNA KALLURAYA^{*ID}, SHARATHA KUMAR and PRIYA

Department of P.G. Studies and Research in Chemistry, Yenepoya Institute of Arts, Science, Commerce and Management, Yenepoya Deemed to be University, Mangaluru-575002, India

*Corresponding author: E-mail: bkalluraya@gmail.com

Received: 21 July 2024;

Accepted: 13 September 2024;

Published online: 30 September 2024;

AJC-21771

A series of novel ethyl-4-methyl-6-phenyl-2-(substituted thio)pyrimidine-5-carboxylate (**4a-m**), ethyl-4-methyl-phenyl-2-(substituted sulfinyl)pyrimidine-5-carboxylate (**5a-m**) and ethyl-4-methyl-phenyl-2-(substituted sulfonyl)pyrimidine-5-carboxylate (**6a-m**) were synthesized by multi-step organic synthesis. The synthesized compounds were characterized by ¹H NMR, ¹³C NMR, LCMS and elemental analysis. Most of the compounds showed significant antibacterial and anticancer activity comparable to or higher than the standard employed.

Keywords: Pyrimidine analogues, Sulfinyl pyrimidine, Sulfonyl derivatives, Antibacterial activity, Anticancer activity.

INTRODUCTION

The nucleophilic substitution of 2-halo pyrimidine derivatives with alkyl or aryl thiols followed by oxidation with *m*-chloroperbenzoic acid (*m*-CPBA) to produce corresponding sulfoxides and sulfones, has garnered significant interest in the synthesis of novel pyrimidine compounds with enhanced pharmacological activity [1,2]. Compounds bearing sulfanyl, sulfinyl and sulfonyl moieties are crucial both medicinally and industrially. They serve as antivirals [3], antineoplastic agents [4] and agrochemicals. For instance, 4-alkylthiopyrimidine derivatives demonstrate broad-spectrum herbicidal activity in transplanted paddy rice [5] and have applications as fungicides [6,7]. Additionally, 6-*n*-propyl-2-thiouracil functions as an antithyroid drug [8], while its *S*-alkylated and *N*-alkylated derivatives exhibit novel antibacterial, antimalarial and cytotoxic properties [9].

Thiouracils and their nucleoside analogues are naturally occurring, with 2-thiouracil commonly found in the t-RNA of *Escherichia coli* [10]. A series of sulfanyl pyrimidine analogues, such as S-DABO, have been reported to possess anti-HIV activities [11,12]. These findings underscore the importance of pyrimidine derivatives in medicinal chemistry and their potential in drug development.

In light of these observations and as part of our ongoing research to identify biologically active pyrimidine derivatives

[13-17], we have synthesized a novel series of ethyl-4-methyl-6-phenyl-2-(substituted thio)pyrimidine-5-carboxylates (**4a-m**), ethyl-4-methyl-6-phenyl-2-(substituted sulfinyl)pyrimidine-5-carboxylates (**5a-m**) and ethyl-4-methyl-6-phenyl-2-(substituted sulfonyl)pyrimidine-5-carboxylates (**6a-m**). These compounds were specifically designed and synthesized focusing on 2-position of the pyrimidine ring, as substitution at this site is known to significantly impact the biological activity of the molecules.

So, present work distinguishes itself by the systematic exploration of the structure-activity relationships (SAR) of these novel pyrimidine analogues, with a particular emphasis on their antibacterial and anticancer activities. This work attempts to clarify the differences in the thio, sulfinyl and sulfonyl substituents influence the pharmacological profiles of these molecules, therefore influencing the development of more potent medicinal drugs.

EXPERIMENTAL

Unless otherwise specified, all chemicals and solvents were obtained from commercial suppliers and used with proper purification whenever required. Reaction time and purity of the products were monitored by TLC on Merck KGaA silica gel 60F₂₅₄ aluminium sheets 20 cm × 20 cm with fluorescent indicator at 254 nm. Column chromatography was run on silica gel (230-400 mesh). All the melting points were recorded on

Buchi M-565 instrument and are uncorrected. The mass spectra (MS) were taken in ESI mode on Agilent Tech 1290 LC-MS. ^1H NMR and ^{13}C NMR spectra were recorded on Bruker ARX-400, 400 MHz spectrometer with TMS as an internal standard.

General procedure

Ethyl-4-methyl-2-oxo-6-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1): A mixture of benzaldehyde (25 g, 9.41 mmol) ethyl acetoacetate (33.7 g, 10.35 mmol), urea (15.56 g, 10.35 mmol) and a catalytic amount of conc. HCl in ethyl alcohol (100 mL) was stirred under reflux for 6 h. The reaction mass was cooled to room temperature and poured into ice-water (500 mL). The resulting precipitate was filtered, washed with water (200 mL), dried under reduced pressure to afford product **1** as an off-white solid (50 g, 82%), m.p.: 122.5-117.9 °C; ^1H NMR (DMSO- d_6) δ ppm: 1.09 (t, 3H, $J = 7.2$ Hz), 2.25 (s, 3H), 3.98 (q, 2H, $J = 7.2$ Hz), 7.25-7.32 (m, 5H, Ar-H), 7.73 (br s, 1H), 9.19 (br s, 1H), ^{13}C NMR (DMSO- d_6) δ ppm: 14.5, 18.2, 54.4, 59.6, 99.7, 126.7, 127.7, 128.8, 145.33, 148.7, 152.5, 165.7; Mass: m/z , 261.2 (M+1).

Ethyl-4-methyl-2-oxo-6-phenyl-1,2-dihydropyrimidine-5-carboxylate (2): To a cooled solution of compound **1** (20 g, 3.84 mmol) in acetone (400 mL) and ceric ammonium nitrate (126.38 g, 11.52 mmol) in water (400 mL) and NaHCO_3 (32.27 g, 19.21 mmol) was added and stirred at room temperature for 12 h. The reaction mass was concentrated under reduced pressure to remove acetone. The aqueous phase was extracted with ether, dried over Na_2SO_4 filtered and concentrated to afford compound **2** as a colourless liquid (yield: 15 g, 75%). ^1H NMR (DMSO- d_6) δ ppm: 0.82 (t, 3H, $J = 7.2$ Hz), 2.39 (s, 3H), 3.94 (q, 2H, $J = 7.2$ Hz), 7.45 (m, 5H), 12.39 (br s, 1H); ^{13}C NMR (DMSO- d_6) δ : 13.6, 61.2, 126.6, 127.9, 128.6, 128.8, 130.5, 155.8, 166.3; Mass: m/z , 259.2 (M+1).

Ethyl-2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylate (3): A solution of compound **2** (10 g, 3.87 mmol) and POCl_3 (36.19 mL, $d = 1.64$ g/cm 3 , 38.71 mmol) was heated at 120 °C for 2 h. The reaction mass was concentrated under reduced pressure, the residue was dissolved in chloroform and was washed with water and a saturated solution of NaHCO_3 . The organic layer was dried over Na_2SO_4 , filtered and concentrated to afford compound **3**. The crude compound **3** was purified by silica gel column chromatography (eluent, 25% EtOAc in petroleum ether) to afford compound **3** as brown liquid (yield: 6 g, 56%). ^1H NMR (DMSO- d_6) δ ppm: 1.03 (t, 3H, $J = 7.2$ Hz), 2.56 (s, 3H), 4.21 (q, 2H, $J = 7.2$ Hz), 7.58 (m, 5H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.6, 62.6, 79.6, 124.7, 128.6, 129.3, 131.4, 136.1, 159.9, 166.0, 166.7, 169.2; Mass: m/z , 277.2 (M+1).

Ethyl-4-methyl-6-phenyl-2-(alkyl/aryl thio)pyrimidine-5-carboxylates (4a-m): To a solution of NaH (1.8 mmol) in dry THF (2 mL) was added alkyl/aryl thiols (1.08 mmol) in THF (2 mL) dropwise at 0 °C and stirred at room temperature for 30 min. A solution of ethyl-2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylate (**3**, 0.905 mmol) in dry THF (2 mL) was added dropwise at 0 °C, slowly the reaction mass was warmed to room temperature and stirred for 2h. The reaction mass was poured into ice water (10 mL), extracted with EtOAc

(25 mL \times 2), washed with brine (25mL) and dried over Na_2SO_4 . The resulting solution was concentrated. The crude was purified by silica gel column chromatography (eluent, 20% EtOAc in petroleum ether) to afford compounds **4a-m**.

Ethyl-4-methyl-6-phenyl-2-(ethylthiopyrimidine-5-carboxylate (4a): Off white solid; yield: 78%, m.p.: 100-102 °C; ^1H NMR (DMSO- d_6) δ ppm: 0.90 (t, 3H, $J = 7.2$ Hz), 0.94 (t, 3H, $J = 7.1$ Hz), 2.68 (s, 3H, CH_3), 4.18 (q, 2H, $J = 7.2$ Hz), 4.22 (q, 2H, $J = 7.1$ Hz), 7.39-7.51 (m, 5H); Mass: m/z , 302 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$: C, 63.55 (66.32); H, 6.00 (5.28); N, 9.26 (5.38).

Ethyl-4-methyl-6-phenyl-2-(phenyl)thiopyrimidine-5-carboxylate (4b): Off white solid; yield: 81%, m.p.: 95-98 °C; ^1H NMR (DMSO- d_6) δ ppm: 0.90 (t, 3H, $J = 7.2$ Hz, CH_3), 2.69 (s, 3H, CH_3), 4.22 (q, 2H, $J = 7.2$ Hz, CH_2), 7.45-7.52 (m, 6H, Ar-H), 7.64 (d, 2H, $J = 7.6$ Hz, Ar-H), 7.94 (d, 2H, $J = 4$ Hz, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.8, 62.9, 125.5, 129.3 (t, $J = 256$ Hz), 131.8 (d, 232 Hz), 136.3, 143.5 (C-S, benzene-S), 164.1 (C=O), 166.6, 167.7, 170.3 (C-S of pyrimidine-S); Mass: m/z , 352 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{20}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$: C, 68.55 (68.51); H, 5.18 (5.20); N, 7.99 (7.97).

Ethyl-4-methyl-6-phenyl-2-(*p*-anisyl)thiopyrimidine-5-carboxylate (4c): Off white solid; yield: 96%, m.p.: 85-87 °C; ^1H NMR (DMSO- d_6) δ ppm: 0.88 (t, 3H, $J = 7.2$ Hz, CH_3), 2.58 (s, 3H, CH_3), 4.09 (q, $J = 7.2$ Hz, 2H, CH_2), 7.12 (d, 2H, $J = 7.8$ Hz, *ortho* protons of *p*-anisyl), 7.38 (d, 2H, $J = 7.8$ Hz *meta* protons of *p*-anisyl), 7.49-7.56 (m, 5H, Ar-H); Mass: m/z , 381 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_3\text{S}$: C, 66.29 (66.32); H, 5.30 (5.28); N, 7.36 (7.38).

Ethyl-4-methyl-6-phenyl-2-(*m*-anisyl)thiopyrimidine-5-carboxylate (4d): White solid; yield: 67%, m.p.: 100-102 °C; ^1H NMR (DMSO- d_6) δ ppm: 1.01 (t, 3H, $J = 7.2$ Hz, CH_3), 2.45 (s, 3H, CH_3), 3.79 (s, 3H, OCH_3), 4.16 (q, 2H, $J = 7.2$ Hz), 7.0-7.4 (m, 4H, Ar-H), 7.46-7.53 (m, 5H, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.8, 55.8, 62.1, 115.9, 120.1, 121.3, 127.1, 128.4, 129.0, 130.1, 130.4, 130.9, 137.1 (C-S, benzene-S), 159.9, 163.3 (C=O), 166.2, 167.4, 171.2 (C-S of pyrimidine-S); Mass: m/z , 397 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_3\text{S}$: C, 66.29 (66.32); H, 5.30 (5.28); N, 7.36 (7.38).

Ethyl-4-methyl-6-phenyl-2-(propyl)thiopyrimidine-5-carboxylate (4e): Off white solid; yield: 80%, m.p.: 130-132 °C; ^1H NMR (DMSO- d_6) δ ppm: 0.83 (t, 3H, $J = 7.1$ Hz, CH_3 of propyl), 0.92 (t, $J = 7.2$ Hz, CH_3 of ethyl), 1.2 (m, 2H, CH_2 of propyl) 4.18 (t, $J = 7.1$ Hz, CH_2), 2.51 (s, 3H, CH_3), 4.48 (q, 2H, $J = 7.4$ Hz, S- CH_2) 7.38-7.49 (m, 5H, Ar-H); Mass: m/z , 317 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{17}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$: C, 64.53 (64.55); H, 6.37 (6.39); N, 8.85 (8.86).

Ethyl-4-methyl-6-phenyl-2-(*p*-aminophenyl)thiopyrimidine-5-carboxylate (4f): White solid; yield: 88%, m.p.: 125-128 °C; ^1H NMR (DMSO- d_6) δ ppm: 1.0 (t, 3H, $J = 7.2$ Hz, CH_3), 2.42 (s, 3H, Ar- CH_3), 4.14 (q, 2H, $J = 7.2$ Hz, CH_2), 5.54 (s, 2H, Ar- NH_2), 6.62 (d, 2H, $J = 8.8$ Hz, Ar-H of *p*-amino phenyl), 7.24 (d, 2H, 8.8 Hz, Ar-H of *p*-amino phenyl), 7.43-7.50 (m, 5 H, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.7, 62.0, 112.3, 114.7, 121.3, 128.7 (d, $J = 224$ Hz), 130.8, 137.0, 137.3, 150.6, 163.2 (C=O) 165.8, 167.6, 173.3 (C-S of pyrimi-

dine-S); Mass: m/z , 366 ($M^+ + 1$). Anal. calcd. (found) % for $C_{20}H_{19}N_3O_2S$: C, 65.73 (65.77); H, 5.24 (5.23); N, 11.50 (11.53).

Ethyl-4-methyl-6-phenyl-2-(*o*-chlorophenyl)thio-pyrimidine-5-carboxylate (4g): Off white solid; yield: 75%, m.p.: 134-136 °C; 1H NMR (DMSO- d_6) δ ppm: 1.1 (t, 3H, $J = 7.2$ Hz, CH_3), 2.38 (s, 3H, Ar- CH_3), 4.08 (q, 2H, $J = 7.2$ Hz, CH_2), 7.38-7.86 (m, 9H, Ar-H); Mass: m/z , 386 ($M^+ + 1$) 388 ($M^+ + 3$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2$: C, 62.41 (62.42); H, 4.45 (4.46); N, 7.28 (7.29).

Ethyl-4-methyl-6-phenyl-2-(*p*-chlorophenyl)thio-pyrimidine-5-carboxylate (4h): Off white solid; yield: 79%, m.p.: 146-148 °C; 1H NMR (DMSO- d_6) δ ppm: 1.00 (t, 3H, $J = 7.2$ Hz, CH_3), 2.45 (s, 3H, CH_3), 4.16 (q, 2H, $J = 7.2$ Hz, CH_2) 7.41 (d, 2H, $J = 8.8$ Hz, Ar-H of *p*-chlorophenyl), 7.55 (d, 2H, 8.8 Hz, Ar-H of *p*-chlorophenyl), 7.45-7.53 (m, 5H, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.7, 62.2, 122.0, 128.0, 128.4, 129.3 (d, $J = 232$ Hz), 130.9, 134.8, 137.0, 163.4 (C=O) 166.3, 167.3, 170.8 (C-S of pyrimidine-S); Mass: m/z , 386 ($M^+ + 1$), 388 ($M^+ + 3$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2S$: C, 62.41 (62.43); H, 4.45 (4.42); N, 7.28 (7.27).

Ethyl-4-methyl-6-phenyl-2-(*o*-bromophenyl)thio-pyrimidine-5-carboxylate (4i): White solid; yield: 81%, m.p.: 120-122 °C; 1H NMR (DMSO- d_6) δ ppm: 0.91 (t, 3H, $J = 7.2$ Hz, CH_3), 2.39 (s, 3H, Ar- CH_3), 4.21 (q, 2H, $J = 7.2$ Hz, CH_2), 7.32-7.51 (m, 9H, Ar-H); Mass: m/z , 429 ($M^+ + 1$), 437 ($M^+ + 3$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2SBr$: C, 55.95 (55.93); H, 3.99 (3.97); N, 6.52 (6.50).

Ethyl-4-methyl-6-phenyl-2-(*m*-bromophenyl)thio-pyrimidine-5-carboxylate (4j): Off white solid; yield: 82%, m.p.: 110-112 °C; 1H NMR (DMSO- d_6) δ ppm: 0.98 (t, 3H, $J = 7.2$ Hz, CH_3), 2.41 (s, 3H, Ar- CH_3), 4.18 (q, 2H, $J = 7.2$ Hz, CH_2), 7.18-7.63 (m, 9H, Ar-H); Mass: m/z , 429 ($M^+ + 1$), 437 ($M^+ + 3$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2SBr$: C, 55.95 (55.90); H, 3.99 (3.98); N, 6.52 (6.51).

Ethyl-4-methyl-6-phenyl-2-(*p*-bromophenyl)thio-pyrimidine-5-carboxylate (4k): White solid; yield: 86%, m.p.: 104-106 °C; 1H NMR (DMSO- d_6) δ ppm: 1.01 (t, 3H, $J = 7.2$ Hz, CH_3), 2.45 (s, 3H, CH_3), 4.16 (q, 2H, $J = 7.2$ Hz, CH_2), 7.41 (d, 2H, $J = 8.8$ Hz, Ar-H of *p*-chlorophenyl), 7.63 (d, 2H, 8.8 Hz, *ortho* protons of *p*-chlorophenyl), 7.47-7.51 (m, 5H, Ar-H), 7.69 (d, 2H, 8.8 Hz, *meta* protons of *p*-chlorophenyl); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.7, 62.2, 122.0, 123.5, 128.4, 128.6, 129.1, 131.0, 132.6, 137.0, 137.2, 164.4 (C=O), 167.3, 170.7 (C-S of pyrimidine-S); Mass: m/z , 429 ($M^+ + 1$), 437 ($M^+ + 3$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2SBr$: C, 55.95 (55.90); H, 3.99 (3.97); N, 6.52 (6.53).

Ethyl-4-methyl-6-phenyl-2-(*o*-fluorophenyl)thio-pyrimidine-5-carboxylate (4l): Brown solid; yield: 82%, m.p.: 78-80 °C; 1H NMR (DMSO- d_6) δ ppm: 1.03 (t, 3H, $J = 7.2$ Hz, CH_3), 2.36 (s, 3H, CH_3), 4.21 (q, 2H, $J = 7.2$ Hz, CH_2), 7.18-7.53 (m, 9H, Ar-H); Mass: m/z , 369 ($M^+ + 1$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2SF$: C, 65.20 (65.21); H, 4.65 (4.66); N, 7.60 (7.61).

Ethyl-4-methyl-6-phenyl-2-(*p*-fluorophenyl)thio-pyrimidine-5-carboxylate (4m): Off white solid; yield: 69%, m.p.: 127-129 °C; 1H NMR (DMSO- d_6) δ ppm: 1.07 (t, 3H, $J = 7.2$ Hz, CH_3), 2.53 (s, 3H, CH_3), 4.18 (q, 2H, $J = 7.2$ Hz,

CH_2), 7.14-7.44 (m, 5H, Ar-H), 7.52 (d, 2H, $J = 6.8$ Hz, Ar-H), 7.65-7.62 (m, 2H, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.7, 62.2, 66.89, 121.9, 124.7, 128.4, 129.1, 130.9, 137.0, 137.9, 138.0, 163.3, 164.2 (C=O), 164.5, 166.2, 167.4, 171.3 (C-S of pyrimidine-S); Mass: m/z , 369 ($M^+ + 1$); Anal. calcd. (found) % for $C_{20}H_{17}N_2O_2SF$: C, 65.20 (65.21); H, 4.65 (4.66); N, 7.60 (7.61).

Ethyl-4-methyl-6-phenyl-2-(substituted sulfinyl)-pyrimidine-5-carboxylate (5a-m): A solution of ethyl-4-methyl-6-phenyl-2-(alkyl/aryl thio)pyrimidine-5-carboxylates (4a-m) (0.66 mmol) in MDC (20 mL) at 0 °C was added *m*-chloroperbenzoic acid (*m*-CPBA) (0.66 mmol) portionwise and stirred at room temperature for 1h. Completion of reaction was monitored by TLC (EtOAc:petroleum ether::1:1). Reaction mass was quenched in ice cold water (20 mL), extracted with EtOAc (25 mL \times 2), washed with saturated $NaHCO_3$ (20 mL), washed with brine (25 mL) and dried over Na_2SO_4 . The resulting solution was purified by column chromatography (60-120 mesh silica gel, 30% EtOAc in petroleum ether) to afford compounds 5a-m.

Ethyl-4-methyl-6-phenyl-2-(ethylsulfinyl)pyrimidine-5-carboxylate (5a): Brown solid; yield: 45%, m.p.: 107-111 °C; IR (KBr, ν_{max} , cm^{-1}): 2921 (C-H *str.*), 1688 (C=O of ester), 1250 (S=O, sulfoxide); 1H NMR (DMSO- d_6) δ ppm: 1.12 (t, 3H, $J = 7.2$ Hz, CH_3), 1.28 (t, 3H, $J = 7.2$ Hz, CH_3), 2.58 (s, 3H, pyrimidine CH_3), 4.22 (q, $J = 7.2$ Hz, $-OCH_2-CH_3$), 4.51 (q, 2H, $J = 7.2$ Hz, O=S- CH_2-CH_3), 7.41-7.52 (m, 5H, Ar-H); Mass m/z ; 313 ($M^+ + 1$); Anal. calcd. (found) % for $C_{16}H_{18}N_2SO_3$: C, 60.36 (60.32); H, 5.70 (5.71); N, 8.80 (8.82).

Ethyl-4-methyl-6-phenyl-2-(phenylsulfinyl)pyrimidine-5-carboxylate (5b): Off white solid; yield: 60%, m.p.: 112-115 °C; IR (KBr, ν_{max} , cm^{-1}): 2938 (C-H *str.*), 1676 (C=O of ester), 1221 (S=O); 1H NMR (DMSO- d_6) δ ppm: 0.90 (t, 3H, $J = 7.2$ Hz, CH_3), 2.69 (s, 3H, pyrimidine CH_3), 4.22 (q, $J = 7.2$ Hz, 2H, CH_2), 7.45-7.52 (m, 6H, Ar-H), 7.64 (d, 2H, $J = 7.6$ Hz, Ar-H), 7.94 (d, 2H, $J = 7.2$ Hz, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.8, 62.6, 125.5, 129.3 (t, $J = 256$ Hz), 131.8 (d, $J = 232$ Hz), 136.3, 143.5 (C-S, benzene-S), 164.1 (C=O), 166.6, 167.7, 173.0 (C-S of pyrimidine-S); Mass m/z ; 367.0 ($M^+ + 1$); Anal. calcd. (found) % for $C_{20}H_{18}N_2O_3S$: C, 65.55 (65.56); H, 4.95 (4.97); N, 7.64 (7.65).

Ethyl-4-methyl-6-phenyl-2-(*p*-anisylsulfinyl)-pyrimidine-5-carboxylate (5c): Brown solid; yield: 57%, m.p.: 83-89 °C; IR (KBr, ν_{max} , cm^{-1}): 2908 (C-H *str.*), 1681 (C=O of ester), 1228 (S=O); 1H NMR ($CDCl_3$) δ ppm: 1.10 (t, 3H, $J = 7.1$ Hz, CH_3), 2.70 (s, 3H, pyrimidine CH_3), 3.84 (s, 3H, OCH_3 of anisyl), 4.23 (q, 2H, $J = 7.1$ Hz, CH_2), 7.00 (d, 2H, $J = 6.8$ Hz, *p*-anisyl protons), 7.45-7.65 (m, 5H, Ar-H), 7.85 (d, 2H, $J = 6.8$ Hz, *p*-anisyl protons); ^{13}C NMR ($CDCl_3$) δ ppm: 13.6, 22.7, 55.5, 62.3, 62.0, 114.7, 127.3, 128.7 (d, $J = 40$ Hz), 130.8, 136.4, 162.3, 164.4 (C=O), 167.1, 167.5, 173.0 (C-S of pyrimidine); Mass m/z ; 397.0 ($M^+ + 2$); Anal. calcd. (found) % for $C_{21}H_{20}N_2O_4S$: C, 63.62 (63.65); H, 5.08 (5.10); N, 7.07 (7.08).

Ethyl-4-methyl-6-phenyl-2-(*m*-anisylsulfinyl)-pyrimidine-5-carboxylate (5d): Brown solid; yield: 72%, m.p.: 112-116 °C; IR (KBr, ν_{max} , cm^{-1}): 2931 (C-H *str.*), 1688 (C=O of ester), 1231 (S=O); 1H NMR ($CDCl_3$) δ ppm: 1.08 (t,

3H, $J = 7.2$ Hz, CH₃), 2.6 (s, 3H, pyrimidine CH₃), 3.71 (s, 3H, OCH₃ of an -anisyl), 4.18 (q, 2H, $J = 7.1$ Hz, CH₂), 7.1-7.65 (m, 9H, Ar-H); Mass m/z ; 396 ($M^+ + 1$); Anal. calcd. (found) % for C₂₁H₂₀N₂O₄S: C, 63.62 (63.65); H, 5.08 (5.10); N, 7.07 (7.09).

Ethyl-4-methyl-6-phenyl-(propylsulfinyl)pyrimidine-5-carboxylate (5e): Off white solid; yield: 45%, m.p.: 118-121 °C; IR (KBr, ν_{\max} , cm⁻¹): 2948, 3023 (C-H *str.*), 1672 (C=O of ester), 1229 (S=O); ¹H NMR (CDCl₃) δ ppm: 0.91 (t, 3H, $J = 7.0$ Hz, CH₃), 1.08 (t, 3H, $J = 7.2$ Hz, CH₃), 1.56 (m, 2H), 1.83 (t, 2H, $J = 7.0$ Hz, CH₂), 2.63 (s, 3H, pyrimidine CH₃), 4.12 (q, 2H, $J = 7.1$ Hz, CH₂), 7.41-7.56 (m, 5H, Ar-H); Mass m/z ; 307 ($M^+ + 1$); Anal. calcd. (found) % for C₁₇H₂₀N₂O₃S: C, 61.42 (61.44); H, 6.06 (6.08); N, 8.43 (8.45).

Ethyl-4-methyl-6-phenyl-(*p*-aminophenylsulfinyl)pyrimidine-5-carboxylate (5f): Brown solid; yield: 68%, m.p.: 131-134 °C; IR (KBr, ν_{\max} , cm⁻¹): 3240 (N-H *str.*), 3046 (C-H *str.*), 1684 (C=O of ester), 1231 (S=O); ¹H NMR (CDCl₃) δ ppm: 1.08 (t, 3H, $J = 7.1$ Hz, CH₃), 2.58 (t, 3H, pyrimidine CH₃), 4.03 (q, 2H, $J = 7.1$ Hz, CH₂), 5.61 (br, 2H, Ar-NH₂), 6.7 (d, 2H, $J = 8.2$ Hz, *ortho* protons of *p*-aminophenyl), 6.93 (d, 2H, $J = 8.2$ Hz *meta* protons of *p*-aminophenyl), 7.31-7.61 (m, 5H, Ar-H); Mass m/z ; 383 ($M^+ + 1$); Anal. calcd. (found) % for C₂₀H₁₉N₃SO₃: C, 62.97 (62.99); H, 4.27 (4.29); N, 11.02 (11.05).

Ethyl-4-methyl-6-phenyl-2-(*o*-chlorophenylsulfinyl)pyrimidine-5-carboxylate (5g): Off white solid; yield: 45%, m.p.: 137-140 °C; IR (KBr, ν_{\max} , cm⁻¹): 3041 (C-H *str.*), 1678 (C=O of ester), 1209 (S=O); ¹H NMR (CDCl₃) δ ppm: 1.16 (t, 3H, $J = 7.1$ Hz, CH₃), 2.49 (t, 3H, pyrimidine CH₃), 4.11 (q, 2H, $J = 7.1$ Hz, CH₂), 7.01-7.9 (m, 9H, Ar-H); Mass m/z ; 402 ($M^+ + 1$), 404 ($M^+ + 3$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SCl: C, 59.92 (62.42); H, 4.45 (4.46); N, 6.99 (7.29).

Ethyl-4-methyl-6-phenyl-2-(*p*-chlorophenylsulfinyl)pyrimidine-5-carboxylate (5h): Off white solid; yield: 45%, m.p.: 125-128 °C; IR (KBr, ν_{\max} , cm⁻¹): 2995 (C-H *str.*), 1681 (C=O of ester), 1219 (S=O); ¹H NMR (CDCl₃) δ ppm: 1.03 (t, 3H, $J = 7.2$ Hz, CH₃), 2.41 (t, 3H, pyrimidine CH₃), 3.98 (q, 2H, $J = 7.2$ Hz, CH₂), 6.86 (d, 2H, $J = 8.4$ Hz, *ortho* protons of *p*-chloro phenyl) 7.36-7.51 (m, 5H, Ar-H), 7.68 (d, $J = 8.0$ Hz, *meta* protons of *p*-chloro phenyl); Mass m/z ; 402 ($M^+ + 1$), 404 ($M^+ + 3$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SCl: C, 59.92 (59.95); H, 4.45 (4.46); N, 6.99 (6.98).

Ethyl-4-methyl-6-phenyl-2-(2-bromophenylsulfinyl)pyrimidine-5-carboxylate (5i): Brown solid; yield: 68%, m.p.: 125-127 °C; IR (KBr, ν_{\max} , cm⁻¹): 2968 (C-H *str.*), 1685 (C=O of ester), 1257 (S=O), 781 (C-Br *str.*); ¹H NMR (DMSO-*d*₆) δ ppm: 1.04 (t, 3H, $J = 7.2$ Hz), 2.58 (s, 3H, pyrimidine CH₃), 4.22 (q, 2H, $J = 7.2$ Hz), 7.51-7.60 (m, 6H, Ar-H), 7.67 (t, 1H, $J = 7.4$ Hz, Ar-H), 7.77 (d, 1H, $J = 7.9$ Hz, Ar-H), 7.88 (d, 1H, $J = 7.84$ Hz, Ar-H); ¹³C NMR (CDCl₃) δ ppm: 13.6, 22.7, 62.2, 121.2, 126.2, 128.4, 128.6, 130.9, 132.8, 136.1, 143.2, 164.3 (C=O), 167.0, 167.8, 171.9 (C-S, pyrimidine-S); Mass m/z ; 447.3 ($M^+ + 2$), 449 ($M^+ + 4$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SBr: C, 53.94 (53.97); H, 3.85 (3.87); N, 6.29 (6.32).

Ethyl-4-methyl-6-phenyl-2-(*m*-bromophenylsulfinyl)pyrimidine-5-carboxylate (5j): Brown solid; yield: 67%,

m.p.: 115-117 °C; IR (KBr, ν_{\max} , cm⁻¹): 2976 (C-H *str.*), 1681 (C=O of ester), 1256 (S=O); ¹H NMR (DMSO-*d*₆) δ ppm: 1.03 (t, 3H, $J = 7.1$ Hz, CH₃), 2.60 (s, 3H, pyrimidine CH₃), 4.21 (q, 2H, $J = 7.0$ Hz, CH₂), 7.52-7.62 (m, 6H, Ar-H), 7.77 (d, $J = 7.9$ Hz, Ar-H), 7.78 (d, 1H, $J = 6.9$ Hz, Ar-H), 7.98 (t, 1H, $J = 2$ Hz, Ar-H); ¹³C NMR (CDCl₃) δ ppm: 13.9, 22.6, 63.5, 124.2, 125.1, 127.6, 128.8, 129.8, 132.8, 136.0, 137.5, 145.9, 164.3 (C=O), 166.2, 167.8, 169.5, 172.9 (C-S, pyrimidine-S); Mass m/z ; 447.3 ($M^+ + 2$), 449 ($M^+ + 4$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SBr: C, 53.94 (53.93); H, 3.85 (3.87); N, 6.29 (6.31).

Ethyl-4-methyl-6-phenyl-2-(*p*-bromophenylsulfinyl)pyrimidine-5-carboxylate (5k): Brown solid; yield: 49%, m.p.: 118-121 °C; IR (KBr, ν_{\max} , cm⁻¹): 3006 (C-H *str.*), 1679 (C=O of ester), 1251 (S=O, sulfoxide); ¹H NMR (DMSO-*d*₆) δ ppm: 0.93 (t, 3H, $J = 7.1$ Hz, CH₃), 2.48 (s, 3H, pyrimidine CH₃), 4.18 (q, 2H, $J = 7.1$ Hz, CH₂), 6.96 (d, 2H, $J = 8$ Hz, *ortho* protons of *p*-bromophenyl), 7.1-7.62 (m, 5H, Ar-H), 7.63 (d, 2H, $J = 8.4$ Hz, *meta* protons of *p*-bromophenyl); Mass m/z ; 447 ($M^+ + 2$), 449 ($M^+ + 1$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SBr: C, 53.94 (53.93); H, 3.85 (3.87); N, 6.29 (6.32).

Ethyl-4-methyl-6-phenyl-2-(2-fluorophenylsulfinyl)pyrimidine-5-carboxylate (5l): Brown solid; yield: 82%, m.p.: 89-93 °C; IR (KBr, ν_{\max} , cm⁻¹): 2951 (C-H *str.*), 1671 (C=O of ester), 1231 (S=O, sulfinyl); ¹H NMR (DMSO-*d*₆) δ ppm: 1.04 (t, 3H, $J = 7.1$ Hz, CH₃), 2.59 (s, 3H, pyrimidine CH₃), 4.22 (q, 2H, $J = 7.0$ Hz, CH₂), 7.41-7.48 (m, 2H, Ar-H), 7.56-7.67 (m, 6H, Ar-H), 7.85 (t, 1H, $J = 6.6$ Hz, Ar-H); ¹³C NMR (CDCl₃) δ ppm: 13.8, 22.8, 62.7, 116.8 ($J = 108$ Hz), 126.2, 127.5, 128.1 (d, $J = 2.75$ Hz), 131.5, 134.8, 136.2, 160.8, 164.1 (C=O), 166.5, 167.8, 178.1 (C-S, pyrimidine-S); Mass m/z ; 385.0 ($M^+ + 1$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SF: C, 62.49 (62.52); H, 4.46 (4.50); N, 7.29 (7.31).

Ethyl-4-methyl-6-phenyl-2-(*p*-fluorophenylsulfinyl)pyrimidine-5-carboxylate (5m): Off white solid; yield: 64%, m.p.: 109-112 °C; IR (KBr, ν_{\max} , cm⁻¹): 2967 (C-H *str.*), 1678 (C=O of ester), 1241 (S=O, sulfoxide); ¹H NMR (DMSO-*d*₆) δ ppm: 1.01 (t, 3H, $J = 7.2$ Hz, CH₃), 2.53 (s, 3H, pyrimidine CH₃), 4.18 (q, 2H, $J = 7.2$ Hz, CH₂), 7.38-7.85 (m, 9H, Ar-H); Mass m/z ; 385 ($M^+ + 1$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₃SF: C, 62.49 (62.51); H, 4.46 (4.48); N, 7.29 (7.32).

Ethyl-4-methyl-6-phenyl-2-(substituted sulfonyl)pyrimidine-5-carboxylate (6a-m): Ethyl-4-methyl-6-phenyl-2-(alkyl/aryl thio)pyrimidine-5-carboxylates (**4a-m**) (0.66 mmol) in MDC (20 mL) was taken and cooled to 0 °C to this solution *m*-CPBA (1.32 mmol) was added portionwise and stirred at room temperature for 1h. Completion of reaction was monitored by TLC (EtOAc:petroleum ether :: 1:1). Reaction mass was quenched in ice cold water (20 mL), extracted with EtOAc (25 mL \times 2), washed with saturated NaHCO₃ (20 mL), washed with brine (25 mL) and dried over Na₂SO₄. The resulting solution was purified by column chromatography (60-120 mesh silica gel, 20% EtOAc in petroleum ether) to afford compounds **6a-m**.

Ethyl-2-(ethylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6a): Brown solid; yield: 45%, m.p.: 111-114 °C; IR (KBr, ν_{\max} , cm⁻¹): 2940 (C-H *str.*), 1768 (C=O of ester), 1402 & 1163 (sulfone asymmetric & symmetric); ¹H NMR

(DMSO- d_6) δ ppm: 1.14 (t, $J = 7.1$ Hz, 3H, CH₃), 4.28 (q, $J = 7.1$ Hz, 2H, CH₂) due to ester CH₃CH₂ 1.49 (t, $J = 7.4$ Hz, 3H, CH₃ of ethyl), 3.64 (q, $J = 7.4$ Hz, 2H, CH₂ of sulfonyl ester), 2.76 (s, 3H, pyrimidine CH₃), 7.48-7.74 (m, 5H, Ar-H); ¹³C NMR (DMSO- d_6) δ ppm: 7.1, 13.8, 22.8, 45.7, 62.8, 129.1 (d, $J = 256$ Hz), 131.6, 136.0, 164.3 (C=O), 166.3, 168.2 (C-S of pyrimidine-S); Mass: m/z , 335 ($M^+ + 1$); Anal. calcd. (found) % for C₁₆H₁₈N₂O₄S: C, 57.47 (57.49); H, 5.43 (5.42); N, 8.38 (8.41).

Ethyl-2-(phenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6b): Brown solid; yield: 45%, m.p.: 114-117 °C; IR (KBr, ν_{\max} , cm⁻¹): 3040 (C-H *str.*), 1691 (C=O of ester), 1393 & 1152 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.12 (t, 3H, $J = 7.2$ Hz, CH₃), 2.70 (s, 3H, pyrimidine CH₃), 4.26 (q, $J = 7.2$ Hz, 2H, CH₂), 7.44-7.63 (m, 7H, Ar-H), 7.65-7.71 (m, 1H, Ar-H), 8.17 (d, 2H, $J = 2.0$ Hz, Ar-H); ¹³C NMR (DMSO- d_6) δ ppm: 13.8, 22.9, 55.5, 62.0, 62.8, 127.2, 128.7, 129.6, 131.7, 135.1, 135.4, 137.8, 164.2 (C=O) 165.3, 166.2, 168.3 (C-S of pyrimidine-S); Mass: m/z , 383 ($M^+ + 1$); Anal. calcd. (found) % for C₂₀H₁₈N₂O₅S: C, 62.81 (62.85); H, 4.74 (4.78); N, 7.33 (7.37).

Ethyl-2-(*p*-anisylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6c): Off white solid; yield: 57%, m.p.: 96-99 °C; IR (KBr, ν_{\max} , cm⁻¹): 2920 (C-H *str.*), 1758 (C=O of ester), 1398 & 1171 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.11 (t, 3H, $J = 7.2$ Hz, CH₃), 2.70 (s, 3H, pyrimidine CH₃), 3.96 (s, 3H, OCH₃), 4.25 (q, 2H, $J = 7.2$ Hz, CH₂), 7.05 (d, 2H, $J = 8.8$ Hz, Ar-H), 7.46 (t, 2H, $J = 7.6$ Hz, Ar-H), 7.52 (d, 1H, $J = 7.2$ Hz, Ar-H), 7.65 (d, 2H, $J = 7.2$ Hz, Ar-H), 8.12 (d, 2H, $J = 8.8$ Hz, Ar-H); ¹³C NMR (DMSO- d_6) δ ppm: 13.8, 22.9, 55.9, 62.6, 115.5, 125.7, 128.7, 134.7, 136.3, 162.3, 164.1 (C=O), 166.7, 167.6, 173.3 (C-S of pyrimidine-S); Mass: m/z , 413 ($M^+ + 1$); Anal. calcd. (found) % for C₂₁H₂₀N₂O₅S: C, 61.15 (61.17); H, 4.89 (4.93); N, 6.79 (6.76).

Ethyl-2-(*m*-anisylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6d): Brown solid; yield: 72%, m.p.: 116-119 °C; IR (KBr, ν_{\max} , cm⁻¹): 2943 (C-H *str.*), 1761 (C=O of ester), 1382 & 1174 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.09 (t, 3H, $J = 7.2$ Hz, CH₃), 2.58 (s, 3H, pyrimidine CH₃), 3.92 (s, 3H, OCH₃), 4.21 (q, 2H, $J = 7.2$ Hz, CH₂), 7.11 (s, 1H, Ar-H), 7.46-7.71 (m, 5H, Ar-H), 7.82-8.1 (m, 3H, Ar-H); Mass: m/z , 413 ($M^+ + 1$); Anal. calcd. (found) % for C₂₁H₂₀N₂O₅S: C, 61.15 (61.12); H, 4.89 (4.86); N, 6.79 (6.81).

Ethyl-2-(propylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6e): Off white solid; yield: 45%, m.p.: 145-148 °C; IR (KBr, ν_{\max} , cm⁻¹): 2970, 3041 (C-H *str.*), 1752 (C=O of ester), 1392 & 1203 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 0.88 (t, 3H, $J = 7.0$ Hz, CH₃ of propyl), 1.12 (t, 3H, $J = 7.2$ Hz, CH₃ of ester), 1.41 (m, 2H, propyl CH₂), 2.16 (t, 2H, $J = 7.0$ Hz, CH₂ of propyl), 2.61 (s, 3H, pyrimidine CH₃), 4.08 (q, 2H, $J = 7.2$ Hz CH₂ of ester), 7.41-7.69 (m, 5H, Ar-H); Mass: m/z , 349 ($M^+ + 1$); Anal. calcd. (found) % for C₁₇H₂₁N₂O₄S: C, 58.60 (58.63); H, 5.79 (5.82); N, 8.04 (8.07).

Ethyl-2-(*p*-aminophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6f): Brown solid; yield: 68%,

m.p.: 133-137 °C; IR (KBr, ν_{\max} , cm⁻¹): 3300 (N-H *str.*), 3040 (C-H *str.*), 1712 (C=O of ester), 1388 & 1191 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.02 (t, 3H, $J = 7.2$ Hz, CH₃), 2.61 (s, 3H, pyrimidine CH₃), 4.18 (q, $J = 7.2$ Hz, 2H, CH₂), 5.16 (br, 2H, NH₂), 6.8 (d, 2H, $J = 8.4$ Hz, *ortho* protons of *p*-amino phenyl) 7.1 (d, 2H, $J = 5.84$ Hz, *meta* protons of *p*-amino phenyl), 7.40-7.64 (m, 5H, Ar-H); Mass: m/z , 398 ($M^+ + 1$); Anal. calcd. (found) % for C₂₀H₁₉N₃O₄S: C, 60.44 (60.42); H, 4.82 (4.86); N, 10.57 (10.55).

Ethyl-2-(*o*-chlorophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6g): Off white solid; yield: 73%, m.p.: 114-118 °C; IR (KBr, ν_{\max} , cm⁻¹): 2980 (C-H *str.*), 1683 (C=O of ester), 1372 & 1208 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.10 (t, 3H, $J = 7.2$ Hz, CH₃), 2.63 (s, 3H, pyrimidine CH₃), 4.26 (q, $J = 7.1$ Hz, 2H, CH₂), 7.49-7.60 (m, 5H, Ar-H), 7.72-7.77 (m, 2H, Ar-H), 7.83 (t, 1H, Ar-H), 8.30 (d, 1H, $J = 1.6$ & 8.0 Hz, Ar-H); ¹³C NMR (DMSO- d_6) δ ppm: 13.8, 22.9, 62.9, 127.6, 128.6, 129.4, 131.8, 132.1, 132.7, 135.5, 136.6, 164.3 (C=O), 164.7, 166.1, 168.6 (C-S of pyrimidine-S); Mass: m/z , 417 ($M^+ + 1$) 419 ($M^+ + 3$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₄SCl: C, 57.62 (57.65); H, 4.11 (4.13); N, 6.72 (6.74).

Ethyl-2-(*p*-chlorophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6h): Brown solid; yield: 63%, m.p.: 146-150 °C; IR (KBr, ν_{\max} , cm⁻¹): 2976 (C-H *str.*), 1673 (C=O of ester) 1381 & 1196 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.06 (t, 3H, $J = 7.2$ Hz, CH₃), 2.58 (s, 3H, pyrimidine CH₃), 4.08 (q, 2H, $J = 7.2$ Hz, CH₂) 6.96 (d, 2H, $J = 8.4$ Hz, *ortho* protons of *p*-chlorophenyl), 7.41-7.58 (m, 5H, Ar-H), 7.71 (d, 2H, 8.4 Hz, *meta* protons of *p*-chlorophenyl); Mass: m/z , 417 ($M^+ + 1$), 419 ($M^+ + 3$); Anal. calcd. (found) % for C₂₀H₁₇ClN₂O₄S: C, 57.62 (57.66); H, 4.11 (4.12); N, 6.72 (6.78).

Ethyl-2-(*o*-bromophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6i): Brown solid; yield: 68%, m.p.: 126-129 °C; IR (KBr, ν_{\max} , cm⁻¹): 3016 (C-H *str.*), 1682 (C=O of ester), 1392 & 1196 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 0.98 (t, 3H, $J = 7.2$ Hz, CH₃), 2.49 (s, 3H, pyrimidine CH₃), 4.11 (q, $J = 7.2$ Hz, 2H, CH₂), 7.81-7.58 (m, 9H, Ar-H); Mass: m/z , 461 ($M^+ + 1$), 463 ($M^+ + 3$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₄SBr: C, 52.07 (52.09); H, 3.71 (3.74); N, 6.07 (6.09).

Ethyl-2-(*m*-bromophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6j): Brown solid; yield: 67%, m.p.: 119-123 °C; IR (KBr, ν_{\max} , cm⁻¹): 2998 (C-H *str.*), 1693 (C=O of ester), 1401 & 1208 (sulfone asymmetric & symmetric); ¹H NMR (DMSO- d_6) δ ppm: 1.03 (t, 3H, $J = 7.1$ Hz, CH₃), 2.53 (s, 3H, pyrimidine CH₃), 4.08 (q, $J = 7.1$ Hz, 2H, CH₂), 7.48-7.62 (m, 5H, Ar-H), 7.81 (s, 1H, Ar-H), 7.88 (d, 1H, $J = 8.8$ Hz, Ar-H), 7.90-8.01 (m, 1H, Ar-H), 8.03 (d, 1H, $J = 8.8$ Hz, Ar-H); Mass: m/z , 461 ($M^+ + 1$) 463 ($M^+ + 3$); Anal. calcd. (found) % for C₂₀H₁₇N₂O₄SBr: C, 52.07 (52.08); H, 3.71 (3.69); N, 6.07 (6.09).

Ethyl-2-(*p*-bromophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6k): Brown solid; yield: 49%, m.p.: 114-118 °C; IR (KBr, ν_{\max} , cm⁻¹): 3011 (C-H *str.*), 1710 (C=O of ester), 1401 & 1168 (sulfone asymmetric & symmetric);

^1H NMR (DMSO- d_6) δ ppm: 1.05 (t, 3H, $J = 7.1$ Hz, CH_3), 2.61 (s, 3H, pyrimidine CH_3), 4.24 (q, $J = 7.1$ Hz, 2H, CH_2), 7.55-7.61 (m, 5H, Ar-H), 7.92 (d, 2H, $J = 8.6$ Hz, Ar-H), 7.98 (d, 2H, $J = 8.6$ Hz, Ar-H); ^{13}C NMR (DMSO- d_6) δ ppm: 13.8, 22.9, 62.9, 127.3, 128.8, 129.4, 131.8, 133.1, 135.8, 136.6, 164.3 (C=O), 164.9, 166.2, 168.4 (C-S of pyrimidine-S); Mass: m/z , 463 ($\text{M}^+ + 2$); Anal. calcd. (found) % for $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_4\text{SBr}$: C, 52.07 (52.08); H, 3.71 (3.68); N, 6.07 (6.09).

Ethyl-2-(*o*-fluorophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6l): Brown solid; yield: 82%, m.p.: 97-101 °C; IR (KBr, ν_{max} , cm^{-1}): 3005 (C-H *str.*), 1695 (C=O of ester), 1404 & 1181 (sulfone asymmetric & symmetric); ^1H NMR (DMSO- d_6) δ ppm: 0.99 (t, 3H, $J = 7.2$ Hz, CH_3), 2.68 (s, 3H, pyrimidine CH_3), 4.18 (q, $J = 7.2$ Hz, 2H, CH_2), 7.38-8.08 (m, 9H, Ar-H); Mass: m/z , 402 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_4\text{SF}$: C, 59.99 (59.97); H, 4.28 (4.31); N, 7.00 (7.03).


Ethyl-2-(*p*-fluorophenylsulfonyl)-4-methyl-6-phenylpyrimidine-5-carboxylate (6m): Off white solid; yield: 64%, m.p.: 129-132 °C; IR (KBr, ν_{max} , cm^{-1}): 2908 (C-H *str.*), 1691 (C=O of ester), 1395 & 1201 (sulfone asymmetric & symmetric); ^1H NMR (DMSO- d_6) δ ppm: 1.03 (t, 3H, $J = 7.2$ Hz, CH_3), 2.64 (s, 3H, pyrimidine CH_3), 4.09 (q, $J = 7.2$ Hz, 2H, CH_2), 7.28-8.10 (m, 9H, Ar-H). Mass: m/z , 402 ($\text{M}^+ + 1$); Anal. calcd. (found) % for $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_4\text{SF}$: C, 59.99 (59.95); H, 4.28 (4.31); N, 7.00 (6.98).

RESULTS AND DISCUSSION

The synthesis of hitherto unreported title compounds was carried out as outlined in **Scheme-I**. The Biginelli reaction between benzaldehyde, ethyl acetoacetate and urea in ethyl alcohol medium employing catalytic amount of conc. HCl afforded dihydropyrimidinone (**1**) as a white solid in 82% yield, compound **1** on oxidation with ceric ammonium nitrate and sodium bicarbonate in acetone and water yielded **2** as a colourless liquid in 75% yield. This on treatment with POCl_3 at 120 °C provided **3** as a brown liquid in 56% yield. The ethyl-2-chloro-4-methyl-6-phenylpyrimidine-5-carboxylate (**3**), when treated with alkyl/aryl/thiols in presence of NaH in THF medium gave ethyl-4-methyl-6-phenyl-2-(alkyl/aryl thio)pyrimidine-5-carboxylates (**4a-m**) in good yields. The ethyl-4-methyl-phenyl-2-(alkyl/aryl sulfinyl)pyrimidine-5-carboxylates (**5a-m**) and ethyl-4-methyl-phenyl-2-(substituted sulfonyl)pyrimidine-5-carboxylate (**6a-m**) were obtained in good yield by treating ethyl-4-methyl-6-phenyl-2-(alkyl/aryl thio)pyrimidine-5-carboxylates (**4a-m**) with 1.0 equiv. and 2.0 equiv. of *m*-CPBA, respectively in dichloromethane medium.

Biological evaluation

In vitro antibacterial activity: The antibacterial activity of the newly synthesized compounds was carried out against four bacterial strains, namely *Staphylococcus aureus*,



Scheme-I

Enterococcus faecalis, *Klebsiella pneumonia* and *Escherichia coli*. The experiment was assessed by Minimum Inhibitory Concentration (MIC) procedure [13]. The results are summarized in Table-1. All the newly synthesized compounds showed moderate to significant antibacterial activity with MIC values ranging from 100 to 0.2 $\mu\text{g/mL}$. Compounds **4c**, **4d**, **4e**, **4j**, **4k**, **5a**, **6a** and **6c** displayed excellent activity against *S. aureus* and *E. faecalis* with overall MIC values of 0.2 $\mu\text{g/mL}$, which were superior to standard ciprofloxacin (MIC value 2 $\mu\text{g/mL}$). However against *E. coli*, compounds **4b**, **4h**, **5a**, **5h**, **6a**, **6d** and **6h** showed moderate activity with overall MIC values of 0.8 $\mu\text{g/mL}$, which are also superior to standard ciprofloxacin (MIC value 2.0 $\mu\text{g/mL}$). Surprisingly against *Klebsiella* only compounds **5l** and **5m** with MIC values of 0.8 $\mu\text{g/mL}$

and 0.4 $\mu\text{g/mL}$, respectively showed moderate activity and none of the other compounds showed any activity comparable with the standard Ciprofloxacin (MIC value 1.0 $\mu\text{g/mL}$).

The introduction of different alkyl/aryl thio groups on C-2 pyrimidine showed major impact on the antibacterial activity against on all four bacterial strains. Particularly, compounds with 4-methoxyphenylthio, 3-methoxyphenylthio and 4-bromophenylthio at C-2 position of pyrimidine (**4c**, **4d** and **4k**) showed marked potency MIC values of 0.2 $\mu\text{g/mL}$ against *S. aureus* and *E. faecalis*, while introduction of other substituents on the C-2 position of pyrimidine **4a-4b**, **4c-4j** and **4l-m** resulted in a less potency against *S. aureus* and *E. faecalis*.

Similar impact also observed on the oxidation of thio groups into corresponding sulfinyl and sulfonyl groups. In particular, a compound with ethylsulfinyl group at the C-2 position of pyrimidine (**5a**) with MIC value of 0.2 $\mu\text{g/mL}$ showed good activity against *S. aureus* and *E. faecalis*. Also, a compound with ethylsulfonyl and 4-methoxyphenyl sulfonyl groups at the C-2 position of pyrimidine (**6a** and **6c**) showed remarkable activity against *S. aureus* and *E. faecalis*.

In vitro anticancer activity: The *in vitro* anticancer activities of all the newly synthesized compounds were screened against three human cancer cell lines A549, K562 and MCF-7 *in vitro*. The *in vitro* cytotoxicity data of test compounds in cells was determined by MIT assay. The results are summarized in Table-2. All target compounds showed moderate to significant anticancer activity against all three cell lines. The most promising compounds **4g** and **5k** displayed significant activity against A549 with IC_{50} values of 28 μM . Compounds **4c**, **4f**, **4h**, **4l**, **4m**, **5c**, **5f**, **5i**, **5j**, **6c**, **6f**, **6k**, **6l** and **6m** displayed moderate activity against A549 cell lines. Whereas compounds **4f**, **4g**, **4h**, **5f**, **5l**, **5m**, **6c**, **6j** and **6k** displayed moderate activity against K562 cell lines and compounds **4g**, **4h**, **4l**, **5k** and **6l** also showed moderate activity against MCF-7 cell lines. The introduction of different alkyl/aryl thio groups on the C-2 position of pyrimidine showed major impact on the anticancer activity against all three cell lines. Comparable impacts were also observed in the oxidation of thio groups to their respective sulfinyl and sulfonyl derivatives.

TABLE-1
ANTIBACTERIAL ACTIVITY DATA OF THE
COMPOUNDS **4a-m**, **5a-m** AND **6a-m** MIC VALUES ($\mu\text{g/mL}$)

Compd.	<i>E. coli</i>	<i>Klebsiella</i>	<i>S. aureus</i>	<i>E. faecalis</i>
4a	1.6	50	0.2	0.8
4b	0.8	50	0.8	0.8
4c	–	25	0.2	0.2
4d	3.12	–	0.2	0.2
4e	3.12	100	0.2	0.4
4f	6.25	–	0.8	0.8
4g	3.12	–	0.8	0.8
4h	0.8	–	0.8	0.4
4i	6.25	–	0.4	0.2
4j	3.12	–	0.2	0.2
4k	6.25	50	0.2	0.2
4l	6.25	–	0.8	0.4
4m	6.25	–	0.2	0.8
Ciprofloxacin (Std)	2.0	1.0	2.0	2.0
5a	0.8	50	0.2	0.2
5b	3.12	100	0.8	0.8
5c	1.6	50	0.2	–
5d	1.6	50	0.2	0.4
5e	1.6	–	0.2	0.4
5f	3.12	–	0.4	0.4
5g	1.6	50	0.4	0.2
5h	0.8	–	0.4	0.2
5i	3.12	–	0.4	0.4
5j	3.12	50	0.2	0.4
5k	1.6	100	0.4	0.8
5l	6.25	0.8	1.6	0.2
5m	12.5	0.4	0.8	0.4
Ciprofloxacin (Std)	2.0	1.0	2.0	2.0
6a	0.8	50	0.2	0.2
6b	12.5	50	0.8	0.4
6c	6.25	100	0.2	0.2
6d	0.8	–	0.2	0.8
6e	50	–	0.4	0.2
6f	1.6	25	0.8	0.4
6g	6.25	–	0.4	0.2
6h	0.8	50	0.8	0.4
6i	25	100	0.4	0.4
6j	6.25	–	0.2	0.4
6k	1.6	100	0.4	0.2
6l	6.25	100	0.4	0.4
6m	12.5	–	0.4	0.2
Ciprofloxacin (Std)	2.0	1.0	2.0	2.0

TABLE-2
In vitro CYTOTOXICITY DATA (IC_{50} μM) OF
COMPOUNDS **4a-m**, **5a-m** AND **6a-m**, AGAINST
CANCER CELL LINES BY MTT ASSAY

Compd.	A549 \pm SD	K562 \pm SD	MCF-7 \pm SD
4a	98 \pm 1.2	82 \pm 1.1	97 \pm 1.1
4b	98 \pm 1.2	97 \pm 1.6	81 \pm 1.4
4c	95 \pm 1.9	73 \pm 1.1	68 \pm 1.1
4d	52 \pm 1.5	92 \pm 1.6	84 \pm 1.9
4e	94 \pm 1.1	83 \pm 1.5	96 \pm 1.3
4f	47 \pm 1.6	42 \pm 1.8	98 \pm 1.6
4g	28 \pm 1.1	47 \pm 1.1	49 \pm 1.9
4h	48 \pm 1.7	45 \pm 1.3	47 \pm 1.1
4i	95 \pm 1.2	96 \pm 1.1	97 \pm 1.2
4j	98 \pm 1.4	84 \pm 1.2	96 \pm 1.1
4k	84 \pm 1.1	68 \pm 1.3	94 \pm 1.8
4l	42 \pm 1.9	83 \pm 1.1	49 \pm 1.1
4m	47 \pm 1.3	98 \pm 1.9	78 \pm 1.4
5-Fu	95 \pm 1.5	41 \pm 1.8	11.5 \pm 1.7

5a	96 ± 1.1	93 ± 1.1	94 ± 1.1
5b	81 ± 1.5	97 ± 1.3	99 ± 1.9
5c	43 ± 1.1	95 ± 1.9	96 ± 1.3
5d	99 ± 1.9	83 ± 1.1	82 ± 1.1
5e	96 ± 1.3	69 ± 1.3	67 ± 1.0
5f	48 ± 1.8	49 ± 1.7	97 ± 1.1
5g	84 ± 1.5	98 ± 1.8	95 ± 1.5
5h	94 ± 1.3	93 ± 1.1	96 ± 1.4
5i	43 ± 1.0	84 ± 1.1	99 ± 1.9
5j	47 ± 1.3	93 ± 1.2	73 ± 1.1
5k	28 ± 1.2	94 ± 1.1	43 ± 1.8
5l	99 ± 1.1	43 ± 1.1	96 ± 1.3
5m	97 ± 1.7	48 ± 1.8	97 ± 1.1
5-Fu	95 ± 1.5	41 ± 1.8	11.5 ± 1.7
6a	94 ± 1.1	99 ± 1.1	84 ± 1.9
6b	81 ± 1.2	92 ± 1.1	97 ± 1.2
6c	45 ± 1.9	47 ± 1.6	98 ± 1.4
6d	8.1 ± 1.0	93 ± 1.7	84 ± 1.0
6e	99 ± 1.8	82 ± 1.1	92 ± 1.3
6f	44 ± 1.7	96 ± 1.9	94 ± 1.2
6g	97 ± 1.7	84 ± 1.4	97 ± 1.9
6h	83 ± 1.9	81 ± 1.8	69 ± 1.1
6i	99 ± 1.3	97 ± 1.1	98 ± 1.8
6j	97 ± 1.1	48 ± 1.2	97 ± 1.1
6k	44 ± 1.6	43 ± 1.0	96 ± 1.8
6l	47 ± 1.5	97 ± 1.8	45 ± 1.9
6m	43 ± 1.4	98 ± 1.8	67 ± 1.5
5-Fu	95 ± 1.5	41 ± 1.8	11.5 ± 1.7

Conclusion

In summary, a series of novel pyrimidine derivatives were designed, synthesized and evaluated their antibacterial and anticancer activities. The preliminary investigations showed that several compounds **4c**, **4d**, **4k**, **5a**, **6a** and **6c** possess excellent antibacterial activity against *S. aureus* and *E. fecalis* *in vitro*. Meanwhile, all the synthesized compounds were also tested for their activity against three cancer cell lines A549, K562 and MCF-7. The most promising compounds **4g** and **5k** showed significant activity with promising IC₅₀ values.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

- X.A.F. Cook, A. de Gombert, J. McKnight, L.R.E. Pantaine and M.C. Willis, *Angew. Chem. Int. Ed.*, **60**, 11068 (2021); <https://doi.org/10.1002/anie.202010631>
- Y.-J. Cherng, *Tetrahedron*, **58**, 4931 (2002); [https://doi.org/10.1016/S0040-4020\(02\)00424-6](https://doi.org/10.1016/S0040-4020(02)00424-6)
- M.S. Masoud, A.A. Ibrahim, E.A. Khalil and A. El-Marghany, *Spectrochim. Acta A Mol. Biomol. Spectrosc.*, **67**, 662 (2007); <https://doi.org/10.1016/j.saa.2006.07.046>
- A. Odani, H. Kozłowski, J. Swiatek-Kozłowska, J. Brasuñ, B.P. Operschall and H. Sigel, *J. Inorg. Biochem.*, **101**, 727 (2007); <https://doi.org/10.1016/j.jinorgbio.2006.12.014>
- L.D. Markley, K.E. Arndt, T.W. Balko, T.M. Bargar, F.R. Green and J.L. Jackson, 222nd ACS National Meeting, Chicao, IL, USA (2001).
- K. Steinbeck and S. Dutzmann, *Chem. Abstr.*, **112**, 55905 (1989).
- E. Tanaka, S. Hayashi, N. Okuma and T. Nakagawa, *Chem. Abstr.*, **111**, 153832 (1989).
- N. Zenker, Thyroid Function and Thyroid Drugs. Principles of Medicinal Chemistry, Lea and Febiger, Philadelphia, London, edn. 3, pp. 603-621 (1990).
- P.F. Lamie and J.N. Philoppes, *J. Enzym. Inhib. Med. Chem.*, **35**, 864 (2020); <https://doi.org/10.1080/14756366.2020.1740922>
- C. Vetter, C. Wagner, G.N. Kaluderovic, R. Paschke and D. Steinborn, *Inorg. Chim. Acta*, **362**, 189 (2009); <https://doi.org/10.1016/j.ica.2008.03.085>
- A. Mai, M. Artico, G. Sbardella, S. Massa, A.G. Loi, E. Tramontano, P. Scano and P. La Colla, *J. Med. Chem.*, **38**, 3258 (1995); <https://doi.org/10.1021/jm00017a010>
- L. Ji, F.-E. Chen, E. De Clercq, J. Balzarini and C. Pannecouque, *J. Med. Chem.*, **50**, 1778 (1995); <https://doi.org/10.1021/jm061167r>
- P.C. Shyma, B. Kalluraya, S.K. Peethambar, S. Telkar and T. Arulmoli, *Eur. J. Med. Chem.*, **68**, 394 (2013); <https://doi.org/10.1016/j.ejmech.2013.07.019>
- B. Lingappa, B. Kalluraya, S.N. Rai and N.S. Kumar, *Organ. Chem. Indian J.*, **2**, 5 (2006).
- A.K. Kadambar, B. Kalluraya and S.M. Kumar, *J. Heterocycl. Chem.*, **57**, 3845 (2020); <https://doi.org/10.1002/jhet.4067>
- H.A.N. Banu, B. Kalluraya, N. Manju, R. Ramu, S.M. Patil, K.M. Lokanatha Rai and N. Kumar, *Chemistry Select*, **8**, e202203578 (2023); <https://doi.org/10.1002/slct.202203578>
- D.V. Geetha, C.L. Sharath, N. Shivakumar, B.N. Lakshminarayana, K.M. Chandini and K. Balakrishna, *J. Mol. Struct.*, **1317**, 139016 (2024); <https://doi.org/10.1016/j.molstruc.2024.139016>